RedChemExpress

Product Data Sheet

Bertilimumab

Cat. No.:	HY-P99474
CAS No.:	375348-49-5
Target:	CCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY		
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research ^[1] .		
Bertilimumab (CAT 213) neutralizes the ability of eotaxin-1 to cause an increase in intracellular calcium signaling (with an IC ₅₀ value of 2.86 nM), migration of CCR3-expressing L1.2 cells (with an IC ₅₀ value of 0.48 nM), and inhibition of the eotaxin1- evoked shape change of human eosinophils in vitro (with an IC ₅₀ of 0.71 nM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 µg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
Animal Model:	Female BALB/c mice (17-21 g) injected human eotaxin1 ^[1] .	
Dosage:	0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, 10 mg/kg	
Administration:	i.v; once	
Result:	Caused a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice.	
	Bertilimumab (CAT 213) potential for allergic dis Bertilimumab (CAT 213) 50 value of 2.86 nM), min evoked shape change of MCE has not independed Bertilimumab (CAT 213) significant dose-dependent also significantly inhibiti inhibition of total cell in MCE has not independed Animal Model: Dosage: Administration:	

REFERENCES

[1]. Sarah Main, et al. A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA